What Epithalon is. And where it comes from
Epithalon (also spelled Epitalon) is a synthetic tetrapeptide (Ala-Glu-Asp-Gly) developed by Russian researcher Vladimir Khavinson and the St. Petersburg Institute of Bioregulation and Gerontology in the 1980s. It is based on epithalamin, a polypeptide extract of the pineal gland. Khavinson's research program produced dozens of peptide bioregulators, short tissue-specific peptides he proposed could restore organ function by acting as gene-expression regulators.
Epithalon is the most-searched of the Russian peptide bioregulators in Western markets. Its core claim, that it activates telomerase and extends telomeres, is mechanistically interesting but has not been independently replicated in large controlled human trials.
Mechanism, in plain English
Khavinson's proposed mechanism for Epithalon involves several pathways:
- Telomerase activation. Cell culture studies suggest Epithalon activates human telomerase reverse transcriptase (hTERT), the catalytic subunit of telomerase. Telomerase maintains telomere length, which declines with each cell division.
- Pineal/melatonin modulation. As a pineal-derived compound, Epithalon may influence melatonin secretion, which plays roles in circadian rhythm, antioxidant defense, and immune function.
- Gene expression. Khavinson has proposed that peptide bioregulators function as "gene switches", binding to specific DNA promoter regions and restoring youthful expression patterns. This mechanism remains under investigation.
What the evidence shows
Telomerase activation. Khavinson et al. 2002 reported that Epithalon increased telomerase activity in human somatic cells in culture. These findings have been cited widely but have limited independent replication.
Animal longevity. Anisimov et al. 2003 reported increased maximum lifespan and reduced tumor incidence in mice treated with Epithalon. Animal longevity data does not translate directly to humans.
Human data. Several small human studies from the Khavinson group report improvements in biomarkers of aging (antioxidant capacity, immune parameters, melatonin levels) in elderly subjects. These studies have small sample sizes and lack independent replication.
The evidence base is scientifically interesting but limited by the concentrated origin from one research group, lack of large independent RCTs, and absence of regulatory review.
FDA status (this month)
Epithalon is not FDA-approved. It is not approved as a drug in any major regulatory jurisdiction. In Russia it is available as a dietary supplement-equivalent under the "peptide bioregulator" category. Last reviewed 2026-08-09.
Common synonyms researchers use
Epithalon · Epitalon · Ala-Glu-Asp-Gly · tetrapeptide-8 (cosmetic ingredient name) · peptide bioregulator
Safety & adverse-event landscape
Published studies report minimal adverse effects for Epithalon. No serious adverse events have been reported in the published human literature. However, the human safety data is sparse and from a limited number of studies. The theoretical concern with telomerase activation is cancer biology: telomerase is upregulated in most cancer cells. No cancer signal has emerged in published Epithalon studies, but long-term oncological safety in humans is not established. Always consult a qualified healthcare provider.
Frequently asked questions
Want the complete anti-aging and longevity peptide reference?
The Peptexa Top-5 free guide covers the most-studied compounds, mechanism, evidence level, and FDA status for each.
What the preclinical evidence shows
The bulk of the published evidence comes from rodent models, tendon transection and Achilles repair, vascular ligation, NSAID-induced gut damage, and fistulizing colitis models. Effects have been reported as positive in tendocyte outgrowth assays, in vascular angiogenesis assays, and in rat colitis models. The most-cited review is Sikiric (2018) in Current Pharmaceutical Design.
Human published data is limited to small case-series reports and registry submissions. There are no large randomized controlled trials to date. The bulk of the discussion in online health communities reflects animal extrapolation, not human-trial data.
Strong preclinical animal research supports investigation into tendon, ligament, and gastrointestinal healing. Human clinical evidence remains limited despite extensive anecdotal use.
FDA status (this month)
BPC-157 is not FDA-approved for any human indication. On July 23-24, 2026, an FDA Pharmacy Compounding Advisory Committee reviewed several peptides including BPC-157 and voted to recommend reviewing whether compounding pharmacies may be allowed to produce them. A rule-making step would be required before any compounding access is granted. And that step is not FDA approval. Coverage: NYT briefing. Last reviewed 2026-08-09.
Common synonyms researchers use
BPC 157 · BPC-157 · Body Protection Compound 157 · PL-14736 (early proprietary designation in the Sikiric et al. literature).
Safety & adverse-event landscape
In the published preclinical literature, BPC-157 has been administered to rodents over short and medium-term protocols without reported mortality. Adverse-event data in humans is limited. The compound's interaction with nitric oxide pharmacology suggests theoretical considerations with vasodilator and cardiovascular medications, consult your provider if you take any.
Peptexa is an educational resource. We do not provide dosing guidance, sourcing recommendations, or protocol advice. Always consult a qualified healthcare provider before any decision that involves a peptide, supplement, or therapeutic compound.
Frequently asked questions
Want this in your inbox weekly?
Get the Peptexa Top-5 free, five compounds, mechanism-led. One email a week. No spam.
The Peptexa Top-5 Free Guide
Five compounds. Mechanism-led. Evidence-ranked. Free PDF, no email required.
Get the Free Guide →